Related Experiment Video
Updated: May 6, 2026
Acupoint Catgut Embedding Therapy in Traditional Chinese Medicine for Managing Allergic Rhinitis
Published on: December 20, 2024
Effectiveness of montelukast in pediatric patients with allergic rhinitis
Ozge Yilmaz1, Derya Altintas, Carmen Rondon
1Celal Bayar University Medical Faculty, Department of Pediatric Allergy and Pulmonology, Manisa, Turkey.
Insights
Montelukast, a leukotriene receptor inhibitor, offers a well-tolerated option for pediatric allergic rhinitis (AR) with minor side effects. Further research is needed to establish its role in treating seasonal and persistent AR in children.
Area of Science:
- Pediatric Allergy and Immunology
- Pharmacology
- Respiratory Medicine
Background:
- Allergic rhinitis (AR) is a prevalent chronic childhood disease with significant morbidity.
- Leukotrienes are key mediators in AR pathogenesis, contributing to inflammation and vascular permeability.
- Therapeutic strategies for AR aim to relieve symptoms, prevent complications, and improve quality of life.
Purpose of the Study:
- To evaluate the efficacy and tolerability of montelukast in treating pediatric allergic rhinitis.
- To explore the potential role of leukotriene receptor antagonism in managing AR in children.
- To assess montelukast's place in therapy, considering combination treatments.
Main Methods:
- Review of montelukast's mechanism as a leukotriene receptor type I inhibitor.
- Analysis of current guidelines recommending montelukast for seasonal AR in children aged six and above.
- Consideration of comparative efficacy against antihistamines and intranasal corticosteroids.
Main Results:
- Montelukast demonstrates variable efficacy in children with AR.
- It is recommended for seasonal AR in children aged six years and above.
- While less effective than other standard treatments, combination therapy may enhance clinical efficacy.
Conclusions:
- Montelukast is a generally well-tolerated option for pediatric AR with a favorable side effect profile.
- Long-term outcomes require further investigation.
- Larger-scale studies are necessary to formulate definitive recommendations for montelukast use in pediatric seasonal and persistent AR.
Abstract:
Allergic rhinitis (AR) is one of the most common chronic diseases of childhood and carries significant morbidity as well as physical and psychosocial consequences. Therapy aims to alleviate clinical symptoms, prevent complications and improve psychosocial consequences. Leukotrienes which are amongst the main mediators in pathogenesis of AR have chemotactic properties and lead to increased vascular permeability. Thus, leukotriene antagonism may be an effective therapeutic option in treatment of allergic diseases, specifically AR. Montelukast which is a leukotriene receptor type I inhibitor has variable efficacy in children with AR and the guidelines recommend its use in children with seasonal AR aged six years and above. Although its efficacy is inferior to anti-histamines and intranasal corticosteroids, combination treatment may warrant clinical efficacy. Therefore, montelukast may be considered to be a well-tolerated therapeutic option for children with AR with minor side effects though long term results need to be assessed. In conclusion, larger scale research enrolling pediatric cases with seasonal and persistent AR are required before concise recommendations about montelukast use in pediatric AR can be made.
More Related Videos
Related Concept Videos
01:19Antiasthma Drugs: Leukotriene Modifiers
Leukotriene modifiers work through two distinct mechanisms:
01:25Antiasthma Drugs: Mast Cell Stabilizers and Anti-IgE Drugs
Mast cell stabilizers, such as cromolyn (also known as sodium cromoglycate) and nedocromil (Tilade), are effective drugs in asthma management. These stabilizers hinder histamine release by skillfully obstructing the activation of mast cells and other cellular entities. Notably, they navigate this task without...
01:17Drugs Used in Lower Respiratory Disorders: Overview
Bronchodilators, the first step of respiration enhancement, come in various forms, each with its own mechanism...
01:20Asthma: Pathogenesis and Management
Asthma is classified as allergic and non-allergic. Allergens such as dust mites, pollen, and pet dander trigger allergic asthma, while factors like cold air, intense emotions, or exercise can induce non-allergic asthma.
01:13Asthma III: Clinical Manifestations
01:24Antiasthma Drugs: Methylxanthines
Theophylline is thought to inhibit phosphodiesterase enzymes, increasing intracellular levels of cyclic adenosine monophosphate (cAMP) and cyclic guanosine monophosphate (cGMP). This rise in cAMP and cGMP concentrations stimulates cardiac function,...